"85% of patients who have DED do not have a lack of tears, they have MGD (Meibomian Gland Dysfunction). And MGD is treatable. That means we have been treating 85% of patients wrong for 50 years!!!"
Daniel Durrie, MD
Eyedetec will Initially Focus on USA Market of $2.4B (30M Patients) – Growing 6.9% CAGR
$4B Global Intraocular Lens Market Excellent Refractive Cataract Outcomes Depend on Treating DED
$14B Global Contact Lens Market
25% of Population >50 y.o.
Coming DED tsunami!